Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07073781

Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation

Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07073781.

📅 31 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07073781
Sponsor
Leeds Beckett University
Start
2025-08-15
ClinicaliQ Trial Snapshot
  • Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07073781.
  • This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted.….
  • Sponsor: Leeds Beckett University.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted. Seventy participants will be randomly assigned to receive either Lab4P or a placebo. The study will assess changes in memory, executive function, and processing speed, along with blood glucose control, cardiovascular function, cholesterol levels, body composition, and markers of inflammation. The study will also analyse changes in the…

Eligibility Snapshot
  • * Aged 18-40 years * Body Mass Index (BMI) between 25.0 and 29.9 kg/m² (classified as overweight) * In good general health (self-reported) * Normal self-reported sleep patterns, with no history of diagnosed sleep disorders * Willing and able to provide informed consent * Able to comply with study procedures, including fasting and oral glucose tolerance testing

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Cardiovascular Disease: Risk Assessment and Reduction (NICE NG238)
Cardiology / Cardiovascular · 27 Mar 2026
Perform CVD risk assessment using Framingham equation or QRISK3 in all adults aged 40–74 years; initiate atorvastatin 20 mg daily if 10-year…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Clinical Brief
The struggle to get hold of medication in England is set to get worse
Cardiology / Cardiovascular · BBC Health · 01 May 2026
Drug supply shortages are affecting multiple therapeutic areas – patients with cardiovascular disease, stroke prevention, ophthalmology, and psychiatric conditions are currently experiencing…
View brief →
Clinical Brief
Women’s voices to be at the heart of renewed health strategy
Cardiology / Cardiovascular · NHS England · 14 Apr 2026
Women's Health Strategy will be renewed with enhanced mechanisms to centre female patient voices in healthcare planning and delivery Strategy aims to…
View brief →
Clinical Brief
Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation
Cardiology / Cardiovascular · MHRA · 24 Oct 2024
A safety review has been conducted by the MHRA following a Yellow Card report concerning a patient who was taking bromocriptine. The…
View brief →